The Claim
Evolocumab significantly reduces the risk of major adverse cardiovascular events by 15% (odds ratio 0.85, 95% confidence interval: 0.80–0.89) in high-risk cardiovascular patients compared to placebo, with consistent benefits observed across myocardial infarction, stroke, and coronary revascularization, following a median follow-up period of 8 months.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called Evolocumab helps lower the chance of serious heart problems like heart attacks and strokes in people at high risk — and it seems to work pretty well over about 8 months.
See the scientific wording
Evolocumab significantly reduces the risk of major adverse cardiovascular events (MACE) by 15% (OR 0.85, 95% CI: 0.80–0.89) in high-risk cardiovascular patients compared to placebo, with consistent benefits across myocardial infarction, stroke, and coronary revascularization, after a median follow-up of 8 months.
What the research says
1 studyThe study looked at the same drug, Evolocumab, in similar patients and found it reduced heart problems by exactly the amount claimed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.